scholarly journals Uric acid, renal function and risk of hypoglycaemia in Chinese type 2 diabetes patients

2016 ◽  
Vol 32 (8) ◽  
pp. 875-882 ◽  
Author(s):  
Yanfeng Ren ◽  
Linong Ji ◽  
Yiming Mu ◽  
Tianpei Hong ◽  
Qiuhe Ji ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Uric Acid ◽  
Diabetes Patients

Interleukin-18 promoter −137 G/C polymorphism (rs187238) is associated with biochemical markers of renal function and cardiovascular disease in type 2 diabetes patients

2020 ◽  
Vol 80 ◽  
pp. 1-7
Author(s):  
Jânio Emanuel Andrade Cavalcante ◽  
Ederson Laurindo Holanda de Sousa ◽  
Raphael de Oliveira Rodrigues ◽  
Glautemberg de Almeida Viana ◽  
Daniel Duarte Gadelha ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Renal Function ◽  
Biochemical Markers ◽  
Interleukin 18 ◽  
Diabetes Patients

scholarly journals Correlation of Serum 1,5-AG with Uric Acid in Type 2 Diabetes Mellitus with Different Renal Functions

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Kai Zhang ◽  
Bizhen Xue ◽  
Yuexing Yuan ◽  
Yao Wang
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Function ◽  
Uric Acid ◽  
Positive Association ◽  
Female Group ◽  
Haemoglobin A1c ◽  
Renal Functions

Aim. Recent studies found that levels of serum uric acid (SUA) were positively associated with serum 1,5-anhydroglucitol (1,5-AG) in subjects with type 2 diabetes mellitus (T2DM). In the current study, we investigated the association between 1,5-AG and UA in T2DM patients with different renal functions. Methods. A total of 405 T2DM patients, 213 men and 192 women, participated in the study. Patients’ clinical information was collected, and serum 1,5-AG, SUA, and other clinical characteristics were measured. Correlation analyses were carried out to analyze their correlation with serum 1,5-AG and SUA. Results. The male group showed higher levels of SUA than the female group (282.1 ± 91.2 and 244.7 ± 71.89 μmol/L, respectively, P<0.01). Pearson’s correlation coefficients determine that SUA was positively associated with 1,5-AG in both men (r=0.213, P<0.05) and women (r=0.223, P<0.05), and such relationship can be influenced by the renal function. The positive association still existed with moderate impaired renal function. Moreover, 1,5-AG had a negative association with haemoglobin A1c (HbA1c) in T2DM subjects with eGFR ≥ 30 mL/min/1.73 m2 (P<0.01). Conclusion. The positive association between SUA and 1,5-AG still exists in T2DM with moderate renal failure. 1,5-AG can still reflect the glucose levels in patients with CKD stages 1-3.

Association of HbA1c, Serum Uric Acid and Non-HDL Cholesterol in Type 2 Diabetes Patients

Metabolism ◽  
2020 ◽  
Vol 104 ◽  
pp. 154063
Author(s):  
Sushil Baral ◽  
Rupesh Kshetri ◽  
Laxman Mandel
Keyword(s):  
Type 2 Diabetes ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Hdl Cholesterol ◽  
Diabetes Patients

scholarly journals Evolution of metabolic syndrome components in patients with autosomal-dominant polycystic kidney disease: a six-year follow-up study

2019 ◽  
Vol 73 ◽  
pp. 598-607
Author(s):  
Maria Pietrzak-Nowacka ◽  
Krzysztof Safranow ◽  
Małgorzata Marchelek-Myśliwiec ◽  
Mariusz Bodnar ◽  
Sylwia Przysiecka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Renal Function ◽  
Uric Acid ◽  
Kidney Disease ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

Aim: Long-term studies show that some metabolic syndrome (MS) components deteriorate renal function in autosomal dominant polycystic kidney disease (ADPKD) patients. The aim of this 6-year follow-up was to analyze early changes of all MS components and their associations with kidney function in the nondiabetic ADPKD patients with normal renal function, compared to controls. Material/Methods: The follow-up physical and laboratory examinations were performed for 39 ADPKD patients (age 43.7 ± 11.4 years) and 44 controls (43.5 ± 9.1 years). Results: We noticed a significant increase in weight, body mass index (BMI), waist, total and LDL cholesterol, C-peptide, uric acid, creatinine and significant decline of HbA1c and e-GFR in the ADPKD group. Increases in waist, uric acid and creatinine concentrations were significantly higher in the ADPKD patients than controls. Both groups showed similar rates of prediabetes, while diabetes developed in 5 controls (with 4 cases of type 2 diabetes and one case of type 1), but not in the ADPKD group (11% vs 0%, P = 0.06 for diabetes, 9% vs 0%, P = 0.12 for type 2 diabetes). The ADPKD group showed a significantly higher percentage of obesity, waist circumferences, systolic/diastolic blood pressure, concentrations of creatinine, urea and uric acid and lower e-GFR. The MS prevalence was comparable; however, the number of MS components was significantly higher in the ADPKD patients (median 2 vs. 1, p = 0.001). Conclusions: The presence of MS does not influence the rate of renal failure progression in nondiabetic ADPKD patients with normal renal function at a 6-year follow-up.

scholarly journals The Effect of Sodium Channel Blocker, Mexiletine, on Body Weight in Type 2 Diabetes Patients with Visceral Obesity

2019 ◽  
Vol 12 ◽  
pp. 117955141882504
Author(s):  
Naohiko Ueno
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Uric Acid ◽  
Waist Circumference ◽  
Diabetic Neuropathy ◽  
Serum Uric Acid ◽  
Visceral Obesity ◽  
Control Group ◽  
Diabetes Patients

Objective: Mexiletine is an anti-arrhythmic agent also used for the treatment of painful diabetic neuropathy. In this study, the effect of mexiletine on body weight was evaluated in type 2 diabetes patients with diabetic neuropathy exhibiting visceral obesity. Methods: Type 2 diabetes patients with neuropathy exhibiting visceral obesity (n = 21) treated by mexiletine (300 mg/day) and a control group of type 2 diabetes patients with the same condition who received vitamin B12 (n = 12) were retrospectively evaluated. Body weight, waist circumference, hemoglobin A1c (HbA1c), blood pressure, liver function, serum lipids, and serum uric acid were assessed before and 6 months after the treatment. Results: Mexiletine significantly decreased body weight and waist circumference. The changes in body weight and waist circumference in 6 months in the mexiletine group were greater than in the control group. In metabolic parameters, there were significant decreases in triglyceride (TG) and serum uric acid. There were positive relationships between the change in body weight and the changes in TG, uric acid, alanine aminotransferase (ALT), and HbA1c. Conclusions: Mexiletine may affect body weight regulation. It ameliorated the metabolic parameters possibly by decreasing visceral fat. Further study should be performed to clarify the mechanism of the effect.

Sign in / Sign up

Export Citation Format

Share Document